Neutral
Valneva's Legal Storm Overshadows Pfizer's Lyme Vaccine Commitment
Valneva's shares have plunged over 43% due to a U.S. legal investigation triggered by the Phase 3 trial data for its Lyme disease vaccine candidate, w...